The oral EGFR tyrosine kinase inhibitor (TKI), erlotinib, is approved by the FDA depending on extend overall survival (OS) in previously treated non-small-cell lung cancer [10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.